Effects of Pneumococcal Conjugate Vaccine 2 Years after Its Introduction, the Netherlands

• DOI: 10.3201/eid1605.091223
• Publication Date: 2010-04-20T15:01:44Z
• Authors: Gerwin D. Rodenburg; Sabine C. de Greeff; Angelique G.C.S. ...; Hester E. de Melker; Leo M. Schouls; Eelko Hak; Lodewijk Spanjaard; Elisabeth A.M. Sa...; Arie van der Ende
• Keywords: Pneumococcal Conjugate Vaccine; Pneumococcal infections; Pneumococcal vaccine; Bacteremia

Abstract In the Netherlands, 7-valent pneumococcal conjugate vaccine (PCV-7) was implemented in a 3+1-dose schedule national immunization program for infants born after April 1, 2006. To assess vaccine's effectiveness, we compared disease incidence before and implementation (June 2004–June 2006 June 2006–June 2008, respectively). We serotyped 2,552 invasive isolates from throughout covering 25% of country's population. Clinical characteristics were extracted hospital records. After 2006, vaccine-serotype (IPD) decreased 90% (95% confidence interval [CI] 68%–97%) children age eligible PCV-7; simultaneously, however, non–vaccine-serotype IPD increased by 71% (not significant), resulting 44% total net reduction CI 7%–66%). rates did not change other groups. PCV-7 offered high protection against vaccinated children, but increases reduced benefits.